Q1 Earnings Estimate for Ovid Therapeutics Issued By Wedbush

Ovid Therapeutics Inc. (NASDAQ:OVID) – Investment analysts at Wedbush boosted their Q1 2025 earnings estimates for shares of Ovid Therapeutics in a report issued on Wednesday, March 12th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.13) per share for the quarter, up from their prior estimate of ($0.15). Wedbush has a “Outperform” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at $0.88 EPS.

Several other equities analysts have also weighed in on OVID. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Ovid Therapeutics in a research note on Wednesday, December 4th. Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research report on Wednesday, January 29th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Ovid Therapeutics currently has an average rating of “Buy” and a consensus target price of $3.20.

Ovid Therapeutics Stock Up 7.4 %

NASDAQ:OVID opened at $0.47 on Monday. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18. Ovid Therapeutics has a 12-month low of $0.42 and a 12-month high of $3.45. The stock’s fifty day simple moving average is $0.64 and its 200-day simple moving average is $0.95. The firm has a market capitalization of $33.10 million, a P/E ratio of -0.99 and a beta of 0.29.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.19 million.

Institutional Investors Weigh In On Ovid Therapeutics

Hedge funds have recently modified their holdings of the business. Takeda Pharmaceutical Co. Ltd. bought a new stake in Ovid Therapeutics during the 4th quarter worth approximately $7,012,000. Kennedy Capital Management LLC increased its position in shares of Ovid Therapeutics by 1.1% during the fourth quarter. Kennedy Capital Management LLC now owns 1,545,387 shares of the company’s stock worth $1,443,000 after acquiring an additional 17,402 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Ovid Therapeutics by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock worth $1,555,000 after acquiring an additional 14,816 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Ovid Therapeutics in the 4th quarter valued at $934,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Ovid Therapeutics by 50.2% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company’s stock worth $881,000 after purchasing an additional 315,126 shares during the period. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.